

Edgar Filing: CHAFIN WILLARD A - Form 4

CHAFIN WILLARD A
 Form 4
 March 05, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

FORM 4
 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16.
 Form 4 or Form 5 obligations may continue.

1. Name and Address of Reporting Person(s)
 Chafin, Willard A.
 3200 Northline Avenue, Suite 360

 Greensboro, NC 27408
2. Issuer Name and Ticker or Trading Symbol
 Tanger Factory Outlet Centers, Inc. (SKT)
3. I.R.S. Identification Number of Reporting Person, if an entity (Voluntary)
4. Statement for Month/Day/Year
 3/5/2003
5. If Amendment, Date of Original (Month/Day/Year)
6. Relationship of Reporting Person(s) to Issuer (Check all applicable)
 Director 10% Owner
 Officer (give title below) Other (specify below)
 Exec. V. P. of Real Estate,
 Operations, Leasing, Marketing
7. Individual or Joint/Group Filing (Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1) Title of Security	2) Trans- action Date (Month/ Day/Year)	3. Trans- action Code Code V	4. Securities Acquired (A) or Disposed of (D) Amount	A or D Price
Common Stock	03/03/03	M	2,500	A \$22.12500
Common Stock	03/03/03	S	2,500	D \$29.71200

Table II (PART 1) Derivative Securities Acquired, Disposed of, or Beneficially Owned (Columns 1

1) Title of Derivative Security	2) Conversion or Exercise Price of Derivative Security	3) Trans- action Date	4) Trans- action Code Code V	5) Number of Derivative Securities Acquired (A) or Disposed of (D) A D
Limited Partnership Unit Option (right to buy) (1)	\$22.12500	03/03/03	M	2,500

Table II (PART 2) Derivative Securities Acquired, Disposed of, or Beneficially Owned (Columns 1

Edgar Filing: CHAFIN WILLARD A - Form 4

1) Title of Derivative Security	3) Transaction Date	7) Title and Amount of Underlying Securities	8) Price of Derivative Security
-		Title	Amount or Number of Shares
Limited Partnership Unit Option (right to buy) (1)	03/03/03	Common Stock	2,500

SIGNATURE OF REPORTING PERSON
 /S/ By: Thomas J. Guerrieri Jr.
 For: Willard A. Chafin
 DATE 03/05/03

order-collapse:collapse;text-align:left;">

Delaware 000-31161 23-2908305
 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
 6154 Nancy Ridge Drive, San Diego, California 92121
 (Address of principal executive offices) (Zip Code)
 858.453.7200
 (Registrant's telephone number, including area code)
 N/A
 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

In this report, “Arena Pharmaceuticals,” “Arena,” “Company,” “we,” “us” and “our” refer to Arena Pharmaceuticals, Inc., and/or one or more of our wholly owned subsidiaries, unless the context otherwise provides. Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc.

Item 7.01 Regulation FD Disclosure.

Our 2016 Annual Stockholders’ Meeting is scheduled for Monday, June 13, 2016. Following such meeting, we plan to make a presentation using the slides attached as Exhibit 99.1 to this Current Report on Form 8-K, which are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Slides for Arena presentation on June 13, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 10, 2016 Arena Pharmaceuticals, Inc.

By: /s/ Amit D. Munshi

Amit D. Munshi
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Slides for Arena presentation on June 13, 2016